ホーム > 市場調査レポート > 医薬品 > 自己免疫疾患治療の世界市場（2009年～2014年）

電話でのお問い合わせ

市場調査レポート

自己免疫疾患治療の世界市場（2009年～2014年）

Autoimmune Treatment (2009 - 2014)

発行	Markets and Markets
出版日	2009年09月	商品コード	99907
ページ情報	英文 159 pages
価格	US$ 4,650 換算 ¥ 374,185 (税抜) PDF by E-mail (Single User License) US$ 5,650 換算 ¥ 454,655 (税抜) PDF by E-mail (Multi User License) US$ 7,150 換算 ¥ 575,360 (税抜) PDF by E-mail (Corporate Use License)

概要
原文目次
関連レポート

原文目次

Abstract

REPORT DESCRIPTION

Autoimmune disorders result from an overactive immune response of a body working against its own cells. The disease is broadly classified into two types: systemic autoimmune diseases, which affect several organs of the body; and localized autoimmune diseases, which affect only one organ. Around 80 autoimmune diseases are recognized under these two categories. The disease affected over 300 million people across the globe in 2009. No defined reasons have been discovered to date for the occurrence of the disorder. Women are more prone to autoimmune diseases, constituting 70%-75% of all autoimmune patients.

The overall market for the treatment of autoimmune disorders is analyzed into the submarkets for applications, products, services, and technologies. The global market for autoimmune disease treatments is estimated to be at $37.84 billion in 2009, and is growing at a CAGR of 12.7% from 2009 to 2014 to reach an estimated $68.81 billion in 2014. The effects of the global meltdown are given careful consideration when forecasting the market.

The application market is further classified into the treatment markets for systemic autoimmune diseases and localized autoimmune diseases. The applications market is dominated mostly by rheumatoid arthritis under the systemic disease segment, while multiple sclerosis is the major application market under the localized disease segment. These two disorders account for 75% of the total applications market. The other major diseases analysed under the application market are psoriasis, lupus, type I diabetes, inflammatory bowel disease, and thyroid disorders, which together account for 15%-20% of the global applications market.

The product market is classified on the basis of the drugs, diagnostic equipments, therapeutic and monitoring equipment. Drugs form the largest segment of the products market, with major drugs such as NSAID, DMARD, biologic DMARD, Avonex, Rebif, Copaxone, Betaseron, and 5-ASA. The services market consists of consultation and diagnosis, therapy and monitoring, and drug development. The wide and increasing prevalence of autoimmune diseases is boosting the drugs market along with the therapy and monitoring market; along with the fact that almost all autoimmune diseases are chronic and have no permanent cure.

The drugs market is estimated to have a revenue of $24.38 billion in 2009, and it is growing with a CAGR of 12.5% from 2009 to 2014. The total services market with therapy and monitoring and drug development as the largest contributor is estimated to be at $9.31 billion in 2009 and it is growing at a CAGR of 14% from 2009 to 2014. Scope of the Report

The report provides market overviews and forecasts as well as market drivers and restraints for the global autoimmune treatment market. In addition, it profiles the top forty market players and their respective autoimmune.

1. Chapter one - Introduction

1.1. KEY TAKE AWAYS
1.2. Report description
1.3. Markets Covered
1.4. STAKEHOLDERS

2. Chapter Two - Summary

3. Chapter Three - Market Overview

3.1. Evolution for Autoimmune treatments
3.2. FOCUS AREAS for the DEVELOPMENT autoimmune treatment
3.3. Defining the overall autoimmune treatment market
3.4. Defining the Autoimmune treatment market by geography

4. Chapter four - global autoimmune treatment market by application

4.1. Systemic Autoimmune Diseases
4.2. Rheumatoid Arthritis (RA)
- 4.2.1. Drivers
  - 4.2.1.1. Large number of people suffer from RA
  - 4.2.1.2. RA requires continuous treatment as it is a chronic disease
  - 4.2.1.3. Large middle adulthood population is more prone to RA
- 4.2.2. Restraints
  - 4.2.2.1. No fixed treatment is available for RA
  - 4.2.2.2. Fewer insurance coverage and reimbursement for RA treatment
- 4.2.3. Global RA Market for Consultation & Diagnosis
- 4.2.4. Global RA market for therapy & monitoring
  - 4.2.4.1. Global DMARD and biologic DMARD Therapy in RA
  - 4.2.4.2. Global Bridge Therapy market in RA
  - 4.2.4.3. Global Other Therapies market in RA
- 4.2.5. Global RA Market for Drugs
  - 4.2.5.1. Global NSAID market in RA
  - 4.2.5.2. Global Corticosteroids Market in RA
  - 4.2.5.3. Global Other Drugs Market in RA
- 4.2.6. Global other products and services market in RA
- 4.2.7. Drug Approvals
4.3. Psoriasis
- 4.3.1. Drivers
  - 4.3.1.1. Psoriasis starts at early age, gives a long earning period
  - 4.3.1.2. Large patient base is driving the market
  - 4.3.1.3. Psoriasis is also genetically transferred
- 4.3.2. Market restraints
  - 4.3.2.1. Over the counter (OTC) drugs can result into adverse drug reactions (ADRs)
  - 4.3.2.2. No specific diagnosis and treatment hinders the market growth
- 4.3.3. Global Consultation & Diagnosis Market in Psoriasis
- 4.3.4. Global therapy & monitoring market in psoriasis
- 4.3.5. Global Drugs Market in Psoriasis
  - 4.3.5.1. Global Anthralin Market in Psoriasis
  - 4.3.5.2. Global Calcipotriene Market in Psoriasis
  - 4.3.5.3. Global NSAIDs market in Psoriasis
4.4. Lupus
4.5. Other Systemic Diseases
4.6. Localized autoimmune Diseases
4.7. Multiple Sclerosis (MS)
- 4.7.1. Drivers
  - 4.7.1.1. MS is a chronic disorder which requires lifetime treatment
  - 4.7.1.2. Large number of MS patients across the globe
  - 4.7.1.3. Increased public awareness is leading to early initiation of treatment
  - 4.7.1.4. Combination of therapies is increasing the growth opportunities
- 4.7.2. Restraints
  - 4.7.2.1. Complicated nature of disease with limited drugs is hindering the market growth
  - 4.7.2.2. Side effects of injectables and high cost of oral drugs is affecting the growth
- 4.7.3. Global Drugs market in multiple sclerosis
- 4.7.4. Drug Approval
4.8. Inflammatory Bowel Disease (IBD)
- 4.8.1. Drivers
  - 4.8.1.1. IBD a genetically transferred disease, increases the incidence of cases
  - 4.8.1.2. Early treatment of IBD is driving the market
  - 4.8.1.3. Lifelong treatment gives a long earning period
- 4.8.2. Restraints
  - 4.8.2.1. Insurance coverage reimbursement problems for IBD patients
- 4.8.3. Global Consultation & Diagnosis Market in IBD
- 4.8.4. Global therapy & monitoring market in IBD
- 4.8.5. Global drugs market in IBD
4.9. Type I diabetes
- 4.9.1. Easy insurance coverage for diabetes patients
- 4.9.2. Type I diabetes is still considered to be a chronic disorder
- 4.9.3. Casual behavior towards treatment is restraining the Market growth
4.10. Thyroid
4.11. Other Localized Autoimmune diseases

5. Chapter five - Global Autoimmune treatment Market By Product

5.1. Drugs
- 5.1.1. Non-Steroidal anti-inflammatory drugs (NSAID)
  - 5.1.1.1. Drivers
  - 5.1.1.2. Restraints
- 5.1.2. GLUCOCORTICOIDS
- 5.1.3. METHOTREXATE
  - 5.1.3.1. Drivers & Restraints
- 5.1.4. Hydroxychloroquine (HCQ)
  - 5.1.4.1. Drivers
  - 5.1.4.2. Restraints
- 5.1.5. Anthralin
- 5.1.6. Calicipotriene
- 5.1.7. Corticosteriods (Steriods)
- 5.1.8. Aminosalicylates/5-ASA/Mesalazine
- 5.1.9. Avonex
- 5.1.10. Rebif
- 5.1.11. Copaxone
  - 5.1.11.1. Fewer side effects is increasing the demand
  - 5.1.11.2. Reduces relapses in relapsing-remitting multiple sclerosis (RRMS)
- 5.1.12. Betaseron
- 5.1.13. Comparison of four MS drugs
- 5.1.14. Other Drugs
5.2. Diagnostic equipment
5.3. Therapeutic and monitoring equipment
5.4. Other Products

6. Chapter six - global services market in autoimmune treatment

6.1. Consultation & Diagnosis
6.2. Therapy and monitoring
6.3. Drug Development
6.4. Drivers
- 6.4.1. Drugs form the mainstream, most revenue-generating treatment
- 6.4.2. Introduction of biosimilars opens up more opportunities

7. Chapter seven - global Technology market in autoimmune treatment

7.1. DMARD AND BIOLOGIC DMARD THERAPY
- 7.1.1. Drivers
  - 7.1.1.1. Effective therapies with biologic DMARD and the availability of multiple drugs
  - 7.1.1.2. Cost-effective treatment is boosting the demand for the therapy
- 7.1.2. Restraints
7.2. Bridge Therapy
7.3. Topical Therapy
7.4. Fecal Bacteriotherapy
7.5. Helminthic Therapy
- 7.5.1. Drivers & Restraints
  - 7.5.1.1. Higher efficacy
  - 7.5.1.2. Expensive treatment hindering the market growth
7.6. Hematopoietic stem cell transplantation
- 7.6.1. Drivers & Restraints
7.7. Recombinant Technology

8. Chapter Eight - Global Autoimmune Treatment Market by Geography

8.1. Autoimmune treatment market in North America
- 8.1.1. North American Autoimmune treatment Market by
- 8.1.2. Application
8.2. Autoimmune treatment market in Europe
- 8.2.1. European autoimmune treatment market by application
8.3. Autoimmune treatment market in Asia Pacific
8.4. Autoimmune treatment market in ROW

9. Chapter Nine - Patent Analysis

9.1. Analysis of patents by geography

10. Chapter Ten - Company Profiles

10.1. 4SC AG
10.2. Abbott Laboratories
10.3. Active Biotech
10.4. Amgen
10.5. Angiotech Pharmaceuticals
10.6. Astellas Pharma
10.7. AstraZeneca Plc
10.8. Autoimmune Inc
10.9. Bayer-Schering Pharmaceuticals
10.10. BioCryst Pharmaceuticals Inc.
10.11. Biogen Idec, Inc.
10.12. Boehringer Ingelheim Gmbh
10.13. Bristol-Myers Squibb Co.
10.14. Centocor, Inc
10.15. Cytokine PharmaSciences, Inc
10.16. Elan Corporation, plc
10.17. Eli Lilly & Co.
10.18. Forest Laboratories, Inc.
10.19. Galderma Laboratories
10.20. Genentech, Inc.
10.21. Glaxo SmithKline Plc
10.22. Isis Pharmaceuticals, Inc.
10.23. Isotechnika, Inc.
10.24. Johnson & Johnson
10.25. Ligand Pharmaceuticals
10.26. Lupin
10.27. Merk Serono SA
10.28. Mitsubishi Tanabe Pharma Corporation
10.29. Novartis
10.30. Pfizer
10.31. Roche
10.32. Sanofi-Aventis
10.33. Schering-Plough
10.34. Teva
10.35. UCB Pharma Inc
10.36. Vertex Pharmaceuticals Incorporated
10.37. Warner Chilcott
10.38. Watson Pharmaceuticals, Inc
10.39. Wyeth
10.40. ZymoGenetics, Inc.

Appendix

1. Table 1
2. U.S. patents
3. Source: MarketsandMarkets
4. Europe Patent List
5. Source: MarketsandMarkets
6. Table 2
7. Japan Patent Table
8. Source: MarketsandMarkets

List of Tables

SUMMARY TABLE GLOBAL MARKET FOR AUTOIMMUNE TREATMENT, BY APPLICATIONS 2007 - 2014 ($ MILLIONS)
TABLE 1 GLOBAL AUTOIMMUNE TREATMENT MARKET 2007 - 2014 ($ MILLIONS)
TABLE 2 GLOBAL SYSTEMIC DISEASES MARKET, BY APPLICATIONS 2007 - 2014 ($ MILLIONS)
TABLE 3 GLOBAL SYSTEMIC DISEASES MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 4 GLOBAL RHEUMATOID ARTHRITIS MARKET, BY APPLICATIONS 2007 - 2014 ($ MILLIONS)
TABLE 5 GLOBAL RHEUMATOID ARTHRITS APPLICATIONS MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 6 GLOBAL RA CONSULTATION & DIAGNOSIS MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 7 GLOBAL RA THERAPY AND MONITORING MARKET, BY TECHNOLOGY 2007 - 2014 ($ MILLIONS)
TABLE 8 GLOBAL RA THERAPY AND MONITORING MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 9 GLOBAL RA DMARD AND BIOLOGIC DMARD THERAPY MARKET BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 10 GLOBAL RA BRIDGE THERAPY MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 11 GLOBAL OTHER RA THERAPIES MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 12 GLOBAL RA DRUGS MARKET, BY PRODUCTS 2007 - 2014 ($ MILLIONS)
TABLE 13 GLOBAL RA DRUGS MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 14 GLOBAL RA NSAID MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 15 GLOBAL RA CORTICOSTERIODS MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 16 GLOBAL OTHER RA DRUGS MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 17 GLOBAL OTHER RA PRODUCTS AND SERVICES MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 18 MAJOR COMPANIES AND THEIR RA PRODUCTS
TABLE 19 MERGERS AND ACQUISITIONS IN THE RA MARKET
TABLE 20 GLOBAL PSORIASIS MARKET, BY PRODUCTS 2007 - 2014 ($ MILLIONS)
TABLE 21 GLOBAL PSORIASIS APPLICATIONS MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 22 GLOBAL PSORIASIS CONSULTATION & DIAGNOSIS MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 23 GLOBAL PSORIASIS THERAPY & MONITORING MARKET, BY TECHNOLOGY 2007 - 2014 ($ MILLIONS)
TABLE 24 GLOBAL PSORIASIS THERAPY AND MONITORING MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 25 GLOBAL PSORIASIS DRUGS MARKET, BY PRODUCTS 2007 - 2014 ($ MILLIONS)
TABLE 26 GLOBAL PSORIASIS DRUGS MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 27 GLOBAL ANTHRALIN PSORIASIS MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 28 GLOBAL CALCIPOTRIENE PSORIASIS MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 29 GLOBAL NSAID PSORIASIS MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 30 MAJOR COMPANIES AND THEIR PSORIASIS PRODUCTS
TABLE 31 MERGERS & ACQUISITIONS IN THE PSORIASIS MARKET
TABLE 32 GLOBAL LUPUS MARKET, BY APPLICATIONS 2007 - 2014 ($ MILLIONS)
TABLE 33 GLOBAL LUPUS MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 34 GLOBAL OTHER SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY APPLICATIONS 2007 - 2014 ($ MILLIONS)
TABLE 35 GLOBAL OTHER SYSTEMIC AUTOIMMUNE DISEASES MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 36 GLOBAL LOCALIZED DISEASES MARKET, BY APPLICATIONS 2007 - 2014 ($ MILLIONS)
TABLE 37 GLOBAL LOCALIZED DISEASES MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 38 GLOBAL MULTIPLE SCLEROSIS APPLICATIONS MARKET 2007 - 2014 ($ MILLIONS)
TABLE 39 GLOBAL MULTIPLE SCLEROSIS APPLICATIONS MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 40 GLOBAL MS DRUGS MARKET, BY PRODUCTS 2007 - 2014 ($ MILLIONS)
TABLE 41 MAJOR COMPANIES AND THEIR MS PRODUCTS
TABLE 42 MERGERS & ACQUISITIONS IN THE MS MARKET
TABLE 43 GLOBAL INFLAMMATORY BOWEL DISEASE MARKET, BY APPLICATIONS 2007 - 2014 ($ MILLIONS)
TABLE 44 GLOBAL INFLAMMATORY BOWEL DISEASE MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 45 GLOBAL IBD CONSULTATION & DIAGNOSIS MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 46 GLOBAL IBD THERAPY & MONITORING MARKET 2007 - 2014 ($ MILLIONS)
TABLE 47 GLOBAL IBD DRUGS MARKET, BY PRODUCTS 2007 - 2014 ($ MILLIONS)
TABLE 48 GLOBAL IBD DRUGS MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 49 MAJOR COMPANIES AND THEIR IBD PRODUCTS
TABLE 50 MERGERS AND ACQUISITIONS IN IBD MARKET
TABLE 51 GLOBAL TYPE I DIABETES MARKET, BY APPLICATIONS 2007 - 2014 ($ MILLIONS)
TABLE 52 GLOBAL TYPE I DIABETES MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 53 MAJOR COMPANIES AND THEIR TYPE I DIABETES PRODUCTS
TABLE 54 MERGERS AND ACQUISITIONS IN THE TYPE I DIABETES MARKET
TABLE 55 GLOBAL THYROID MARKET, BY APPLICATIONS 2007 - 2014 ($ MILLIONS)
TABLE 56 GLOBAL THYROID MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 57 GLOBAL OTHER LOCALIZED AUTOIMMUNE DISEASES MARKET BY APPLICATIONS 2007 - 2014 ($ MILLIONS)
TABLE 58 GLOBAL OTHER LOCALIZED AUTOIMMUNE DISEASES MARKET BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 59 GLOBAL AUTOIMMUNE TREATMENT MARKET, BY PRODUCT 2007 - 2014 ($ MILLIONS)
TABLE 60 GLOBAL AUTOIMMUNE TREATMENT PRODUCTS MARKET BY GEOGRAPHY 2007 - 2014, ($ MILLIONS)
TOTAL 61 GLOBAL AUTOIMMUNE DRUGS MARKET, BY PRODUCTS 2007 - 2014 ($ MILLIONS)
TOTAL 62 GLOBAL AUTOIMMUNE DRUGS MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 63 GLOBAL NSAID MARKET IN AUTOIMMUNE TREATMENT, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 64 GLOBAL GLUCOCORTICOIDS MARKET IN AUTOIMMUNE TREATMENT BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 65 GLOBAL METHOREXATE MARKET IN AUTOIMMUNE TREATMENT BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 66 GLOBAL HCQ MARKET IN AUTOIMMUNE TREATMENT, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 67 GLOBAL HCQ MARKET IN AUTOIMMUNE TREATMENT, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 68 GLOBAL CALCIPOTRIENE MARKET IN AUTOIMMUNE TREATMENT BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 69 GLOBAL CORTICOSTERIODS MARKET IN AUTOIMMUNE TREATMENT BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 70 GLOBAL AMINOSALICYLATES/5-ASA/MESALAZINE MARKET IN AUTOIMMUNE TREATMENT, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)TTABLE 71 GLOBAL AVONEX MARKET IN AUTOIMMUNE TREATMENT, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 72 GLOBAL REBIF MARKET IN AUTOIMMUNE TREATMENT, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 73 GLOBAL COPAXONE MARKET IN AUTOIMMUNE TREATMENT BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 74 GLOBAL BETASERON MARKET IN AUTOIMMUNE TREATMENT BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 75 GLOBAL OTHER AUTOIMMUNE DRUGS MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 76 GLOBAL AUTOIMMUNE DIAGNOSTIC EQUIPMENT MARKET, BY PRODUCTS 2007 - 2014 ($ MILLIONS)
TABLE 77 GLOBAL AUTOIMMUNE DIAGNOSTIC EQUIPMENT MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 78 GLOBAL AUTOIMMUNE THERAPEUTIC AND MONITORING EQUIPMENT MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 79 GLOBAL OTHER AUTOIMMUNE PRODUCTS MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 80 GLOBAL SERVICES MARKET IN AUTOIMMUNE TREATMENT 2007 - 2014 ($ MILLIONS)
TABLE 81 GLOBAL SERVICES MARKET IN AUTOIMMUNE TREATMENT BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 82 GLOBAL AUTOIMMUNE CONSULTATION & DIAGNOSIS MARKET BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 83 GLOBAL AUTOIMMUNE THERAPY & MONITORING MARKET BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 84 GLOBAL AUTOIMMUNE DRUG DEVELOPMENT MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 85 GLOBAL AUTOIMMUNE TREATMENT TECHNOLOGY MARKET, BY PRODUCTS 2007 - 2014 ($ MILLIONS)
TABLE 86 GLOBAL AUTOIMMUNE TREATMENT TECHNOLOGY MARKET BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 87 GLOBAL DMARD AND BIOLOGIC DMARD TECHNOLOGY MARKET BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 88 GLOBAL AUTOIMMUNE BRIDGE THERAPY MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 89 GLOBAL AUTOIMMUNE TOPICAL THERAPY MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 90 GLOBAL AUTOIMMUNE PHOTOTHERAPY MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 91 GLOBAL AUTOIMMUNE HELMINTHIC THERAPY MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 92 GLOBAL AUTOIMMUNE HEMATOPOIETIC STEM CELL TRANSPLANTATION MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 93 GLOBAL AUTOIMMUNE RECOMBINANT TECHNOLOGY MARKET BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 94 GLOBAL AUTOIMMUNE TREATMENT MARKET, BY GEOGRAPHY 2007 - 2014 ($ MILLIONS)
TABLE 95 NORTH AMERICAN AUTOIMMUNE TREATMENT MARKET, BY APPLICATIONS 2007 - 2014 ($ MILLIONS)
TABLE 96 EUROPEAN AUTOIMMUNE TREATMENT MARKET, BY APPLICATIONS 2007 - 2014 ($ MILLIONS)
TABLE 97 ASIA PACIFIC AUTOIMMUNE TREATMENT MARKET, BY APPLICATIONS 2007 - 2014 ($ MILLIONS)
TABLE 98 ROW AUTOIMMUNE TREATMENT MARKET, BY APPLICATIONS 2007 - 2014 ($ MILLIONS)
TABLE 99 U.S. PATENTS
TABLE 100 EUROPE PATENT LIST
TABLE 101 JAPAN PATENT TABLE